line, established from a patient with AML FAB subtype M2, were also analysed.
Sample preparation
Preparation of Biotinylated cRNA and profiling with Human Genome U133 Gene Chips was performed according to standard protocols (Affymetrix, Santa Clara, CA, USA). Cell lines were analysed in duplicate, clinical samples were analysed with one chip per patient. The array images were quantified utilising Micro Array Suite (MAS) software (Affymetrix).
Microarray quality control and normalisation
After visual inspection of each microarray scan for irregularities, the quality of the whole microarray set was assessed using the 'affyPLM' package from the Bioconductor project (Gentleman et al, 2004) . Expression values were obtained after background subtraction , normalisation (Bolstad et al, 2003) and probe set summarisation on a logarithmic (base 2) scale with the 'affy' package .
Data analysis
Hierarchical clustering analysis of expression profiles was performed using one minus Pearson's correlation coefficient as a measure of pairwise distance between samples and Ward's linkage as the agglomeration method. All 22'216 probe sets were used. The differential expression between fresh clinical samples and cell line samples was assessed using an empirical Bayes test statistic (Smyth, 2004) available through the 'limma' software package (Smyth et al, 2005) . The obtained P-values were corrected for multiple testing using the False Discovery Rate method (Benjamini & Hochberg, 1995) .
GOstat (Beissbarth & Speed, 2004) was used to perform a gene ontology analysis of differentially expressed genes. A separate analysis was carried out for the top 1000 up-and top 1000 downregulated genes.
Results
A hierarchical clustering analysis was performed to investigate the global similarity between the 20 expression profiles (Fig 1A) . Remarkably, the main split in the dendrogram perfectly separated leukaemic cell lines from fresh patient samples. Cell lines clustered with a distinct common expression profile, and accordingly, the dendrogram united both fresh AML and CML samples in a separate common group. Specifically, the K562 and the NB4 cell lines did not cluster with the clinical samples bearing the same chromosomal translocation, i.e. with the CML and the APL samples respectively. In contrast, CML patient samples were clearly separated from fresh AML samples, which in turn clustered according to their morphological and biological features [APL (M3) or acute monocytic leukaemia (M5) respectively]. The correlation matrix (Fig 1B) visualises the pairwise similarity of all fresh patient samples and cell lines directly. Surprisingly, the K562 cell line showed a higher resemblance to AML samples than to CML samples. Table I displays the top 24 probe sets ordered by decreasing evidence for differential expression between fresh samples and cell lines (See also Tables SI, SII, SIII) . For example, the E2F6 gene was upregulated in cell lines compared with clinical samples. It belongs to a group of genes that have a pivotal role in the regulation of cellular proliferation by controlling the expression of genes that are essential for either entry into, or passage through, the cell cycle (Bell & Ryan, 2004) .
A gene ontology analysis of the top 1000 discriminatory genes showed that genes with an increased expression in cell lines were significantly related to macromolecular synthesis and nucleic acid metabolism. Genes with an increased expression in fresh patient samples, on the other hand, were 
Discussion
Much of our knowledge on the molecular functional pathways of human leukaemia is derived from experiments with cell lines rather than from work on clinical samples (Sandberg & Ernberg, 2005) . In our present comparison we would have expected that, for example, BCR/ABL-positive leukaemias, i.e. the clinical material and the respective cell line, would primarily be allocated to a common gene expression profile group, and clearly be separated from BCR/ABL-negative leukaemias, given the strong impact of the BCR/ABL fusion gene in the molecular pathology of CML. However, we found that differences between leukaemia subtypes were dominated by stronger and consistent differences between cell lines and clinical samples. This observation indicates that the most important common denominator of cell lines at a molecular level are gene alterations linked to their immortalisation (an essential feature of any type of cancer cell line), which, in terms of gene expression, apparently overrule type-specific gene alterations, such as chromosomal translocations that define the respective clinical entities. The gene ontology analysis confirmed this hypothesis and showed that in cell lines, genes related to DNA or RNA metabolism and genes related to macromolecule synthesis are particularly active. In contrast, in clinical samples, genes related to immune or host response are overexpressed.
We believe that these observations must be taken into account when experimental data on the molecular pathology of leukaemia obtained from leukaemic cell lines are extrapolated to clinical samples, given the fundamental differences in gene expression profiles between the two groups.
Nuclear receptor subfamily 2, group F, member 2 3 218976_at DNAJC12 3AE3 4 AE9 · 10
DnaJ (Hsp40) homologue, subfamily C, member 12 4 205194_at
Phosphoserine phosphatase 5 219371_s_at
Kruppel-like factor 2 (lung) 6 209434_s_at PPAT 2AE1 2 AE1 · 10
Phosphoribosyl pyrophosphate amidotransferase 7 208961_s_at COPEB )3AE5 2 AE9 · 10
Core promoter element binding protein 8 204228_at
Peptidyl prolyl isomerase H 9 205394_at CHEK1 2AE1 5 AE2 · 10 Replication factor C (activator 1) 2, 16 209406_at
BCL2-associated athanogene 2 17 209891_at
Kinetochore protein Spc25 18 203281_s_at
Ubiquitin-activating enzyme E1-like 19 204795_at PRR3 1AE3 2 AE3 · 10
Proline rich 3 20 209832_s_at CDT1 3AE0 2 AE3 · 10
DNA replication factor 21 222024_s_at
A kinase (PRKA) anchor protein 13 22 209900_s_at
Solute carrier family 16 23 203957_at
E2F transcription factor 6 24 213320_at
HMT1 hnRNP methyltransferase-like 3
Positive (or negative) mean log 2 fold change indicates upregulation (or downregulation) in cell lines compared with fresh samples (refer to Table S1 . for the extensive gene list).
P-values were adjusted to account for multiple testing with a false discovery rate approach (Benjamini & Hochberg, 1995) .
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Supplementary material
The following supplementary material is available for this article online: Table SI . This Table lists all probe sets, ordered by decreasing evidence for differential expression between fresh samples (CML, AML M3, AML M5) and cell lines (K562, NB4, HL60). Positive log fold changes indicate upregulations in cell lines compared with fresh samples. When multiple probe sets were reporting for the same gene, only the most significant was kept. Table SII . GO analysis of top 1000 upregulated genes (overexpression in cell lines compared with clinical samples). Table SIII . GO analysis of top 1000 downregulated genes (underexpression in cell lines compared with clinical samples).
